Product Description
Ketoprofen is a nonsteroidal antiinflammatory drug (NSAID) used in treatment of acute pain and chronic arthritis. Ketoprofen has been linked to a low rate of serum enzyme elevations during therapy and to rare instances of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ketoprofen)
Mechanisms of Action: COX1 Inhibitor,COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical,Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy, Spain, United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Chronic Pain|Low Back Pain
Phase 1: Labor Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-513940-27-00 | P2 |
Unknown Status |
Low Back Pain|Chronic Pain |
2025-10-30 |
|
| 2021-001629-38 | P2 |
Active, not recruiting |
Chronic Pain|Low Back Pain |
2022-10-16 |
|
| KLG0120 | P1 |
Completed |
Labor Pain |
2022-03-30 |